Pathologic Effects of Oral Contraceptives

  • George D. Hilliard
  • Henry J. Norris
Part of the Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer book series (RECENTCANCER, volume 66)


Much information has accumulated on the pathologic effects of oral contraceptive steroids. Many of the reports of untoward effects of oral contraceptives are anecdotal, but it is through the accumulation of isolated case studies that the impetus is given to initiate well-planned clinical and epidemiologic investigations, which in turn establish a scientific basis for any pathologic effects that have occurred. Oral contraceptives have been reported to cause abnormalities in organ systems of the liver (discussed in another paper in this monograph), cervix, endometrium, breast, ovary, vasculature, and in the complex systems of coagulation, renin-angiotensin, carbohydrate, and lipid metabolism, and also with endocrine interrelations. In this chapter, the organ systems will be discussed in turn; for the systemic effects, the reader will be referred to reviews.


Oral Contraceptive Endometrial Carcinoma Pathologic Effect Oral Contraception Endometrial Stromal Sarcoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    ACOG Technical Bulletin Number 41. Oral contraception (1976)Google Scholar
  2. 2.
    Alkjaersig, N., Fletcher, A., Burstein, R.: Association between oral contraceptive use and thromboembolism: A new approach to its investigation based on plasma fibrinogen chromatography. Am. J. Obstet. Gynecol. 122, 199–211 (1975)PubMedGoogle Scholar
  3. 3.
    De Alvarez, R. R., Jahed, F. M., Spitalny, K. J., Elkin, H., Jaunakais, I.: The influence of oral contraceptive steroids on serum lipids. Am. J. Obstet. Gynecol. 116, 727–749 (1973)PubMedGoogle Scholar
  4. 4.
    Ambrus, J. L., Mink, I. B., Courey, N. G., Niswander, K., Moore, R. H., Ambrus, C. M., Lillie, M. A.: Progestational agents and blood coagulation. VII. Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: Summary report of a ten-year study. Am. J. Obstet. Gynecol. 125, 1057–1062 (1976)PubMedGoogle Scholar
  5. 5.
    Andrews, W. C.: Oral contraception: a review of reported physiological and pathological effects. Obstet. Gynecol. Surv. 26, 477–499 (1971)PubMedGoogle Scholar
  6. 6.
    Ariel, I. M.: Enovid therapy (norethynodrel with mestranol) for fibrocystic disease. Am. J. Obstet. Gynecol. 117, 453–459 (1973)PubMedGoogle Scholar
  7. 7.
    Arthes, F. G., Sartwell, P. E., Lewison, E. F.: The pill, estrogens and the breast: epidemiologic aspects. Cancer 28, 1391–1394 (1971)PubMedGoogle Scholar
  8. 8.
    Ayre, J. E., Hillemanns, H. G., Leguerrier, J., Arsenault, J.: Influence of norethynodrel and mestranol upon cervical dysplasia and carcinoma in situ. Obstet. Gynecol. 28, 90–98 (1966)PubMedGoogle Scholar
  9. 9.
    Azzopardi, J. G., Zayid, I.: Synthetic progestogen-oestrogen therapy and uterine changes. J. Clin. Pathol. 20, 731–738 (1967)PubMedGoogle Scholar
  10. 10.
    Beckerhoff, R., Luetscher, J. A., Wilkinson, R., Gonzales, C., Nokes, G. W.: Plasma renin concentration, activity, and substrate in hypertension induced by oral contraceptives. J. Clin. Endocrinol. Metab. 34, 1067–1073 (1972)PubMedGoogle Scholar
  11. 11.
    Beral, V.: Cardiovascular disease mortality trends and oral contraceptive use in young women. Lancet 2, 1047–1052 (1976)PubMedGoogle Scholar
  12. 12.
    Berge, B. S. ten: Histological changes in ovarian and uterine blood vessels after the use of oral contraceptive agents (estrogen-gestagen combinations) and gestagens. Int. J. Fertil. 18, 57–63 (1973)Google Scholar
  13. 13.
    Bick, R. L., Thompson, W. B.: Fibrinolytic activity: changes induced with oral contraceptives. Obstet. Gynecol. 39, 213–217 (1972)PubMedGoogle Scholar
  14. 14.
    Boling, J. L.: Endocrinology of oviductal musculature. In: The Mammalian Oviduct: Comparative Biology and Methodology. Hafez, E. S. E., Blandau, R. J. (Eds.). Chicago: The University of Chicago Press 1969, pp. 163–181Google Scholar
  15. 15.
    Boston Collaborative Drug Surveillance Program. Oral contraceptives and venous thromboembolic disease. Surgically confirmed gallbladder disease and breast tumors. Lancet 1, 1399–1404 (1973)Google Scholar
  16. 16.
    Boyce, J. G., Lu, T., Nelson, J. H., Joyce, D.: Cervical carcinoma and oral contraception. Obstet. Gynecol. 40, 139–146 (1972)PubMedGoogle Scholar
  17. 17.
    Brakman, P., Albrecktsen, O. K., Astrup, T.: Blood coagulation, fibrinolysis and contraceptive hormones. JAMA 199, 69–74 (1967)PubMedGoogle Scholar
  18. 18.
    Brenner, R. M.: The biology of oviductal cilia. In: The Mammalian Oviduct: Comparative Biology and Methodology. Hafez, E. S. E., Blandau, R. J. (Eds.). Chicago: The University of Chicago Press, 1969, pp. 203–229Google Scholar
  19. 19.
    Candy, J., Abell, M. R.: Progestogen-induced hyperplasia of the cervix. JAMA 203, 323–326 (1968)Google Scholar
  20. 20.
    Cohen, C. J., Deppe, G.: Endometrial carcinoma and oral contraceptive agents. Obstet. Gynecol. 49, 390–392 (1977)PubMedGoogle Scholar
  21. 21.
    Collaborative Group for the Study of Stroke in Young Women: Oral contraception and increased risk of cerebral ischemia or thrombosis. New. Engl. J. Med. 288, 871–878 (1973)Google Scholar
  22. 22.
    Comhaire, F., Vandeweghe, M., Vermeulen, A.: Vascular incidents and oral contraceptives: arterial versus venous thromboembolism: a statistical study. Contraception 3, 301–312 (1971)Google Scholar
  23. 23.
    Craig, J. M.: The pathology of birth control. Arch. Pathol. 99, 233–236 (1975)PubMedGoogle Scholar
  24. 24.
    Crane, M. G., Harris, J. J.: Plasma renin activity and aldosterone excretion rate in normal subjects. II. Effects of oral contraceptive agents. J. Clin. Endocrinol. Metab. 29, 558–562 (1969)PubMedGoogle Scholar
  25. 25.
    Czernobilsky, B., Kessler, I., Lancet, M.: Cervical adenocarcinoma in a woman on long-term contraceptives. Obstet. Gynecol. 43, 517–521 (1974)PubMedGoogle Scholar
  26. 26.
    Dickey, R. P., Dorr, C. H., II.: Oral contraceptives: Selection of the proper pill. Obstet. Gynecol. 33, 273–287 (1969)PubMedGoogle Scholar
  27. 27.
    Dickey, R. P., Stone, S. C.: Progestational potency of oral contraceptives. Obstet. Gynecol. 47, 106–112 (1976)PubMedGoogle Scholar
  28. 28.
    Diczfalusy, E.: Mode of action of contraceptive drugs. Am. J. Obstet. Gynecol. 100, 136–163 (1968)PubMedGoogle Scholar
  29. 29.
    Dougherty, C. M.: Cervical cytology and sequential birth control pills. Obstet. Gynecol. 36, 741–744 (1970)PubMedGoogle Scholar
  30. 30.
    Drill, V. A., Martin, D. P., Hart, E. R., McConnell, R. G.: Effects of oral contraceptives on the mammary glands of Rhesus monkeys: a preliminary report. J. Natl. Cancer Inst. 52, 1655–1657 (1974)PubMedGoogle Scholar
  31. 31.
    FDA Drug Bull. 6, 26–27 (1976)Google Scholar
  32. 32.
    Fechner, R. E.: Atypical leiomyomas and synthetic progestin therapy. Am. J. Clin. Pathol. 49, 697–703 (1968)PubMedGoogle Scholar
  33. 33.
    Fechner, R. E.: Fibroadenomas in patients receiving oral contraceptives: a clinical and pathologic study. Am. J. Clin. Pathol. 53, 857–864 (1970a)PubMedGoogle Scholar
  34. 34.
    Fechner, R. E.: Fibrocystic disease in women receiving oral contraceptive hormones. Cancer 25, 1332–1339 (1970b)PubMedGoogle Scholar
  35. 35.
    Fechner, R. E.: The surgical pathology of the reproductive system and breast during oral contraceptive therapy. In: Genital and Mammary Pathology Decennial 1966–1975. Sommers, S. C. (Ed.). New York: Appleton-Century Crofts, 1975, pp. 103–126Google Scholar
  36. 36.
    Flowers, C. E., Jr., Vorys, N., Stevens, V., Miller, A. T., Jensen, L.: The effects of suppression of menstruation with ethynodiol diacetate upon the pituitary, ovary, and endometrium. Am. J. Obstet. Gynecol. 96, 784–803 (1966)PubMedGoogle Scholar
  37. 37.
    Fredricsson, B., Bjorkman, N.: Morphologic alterations in the human oviduct epithelium induced by contraceptive steroids. Fertil. Steril. 24, 19–30 (1973)PubMedGoogle Scholar
  38. 38.
    Gambrell, R. D., Jr., Bernard, D. M., Sanders, B. I., Vanderburg, N., Buxton, S. J.: Changes in sexual drives of patients on oral contraceptives. J. Reprod. Med. 17, 165–171 (1976)PubMedGoogle Scholar
  39. 39.
    Gambrell, R. D., Jr., Greenblatt, R. B., Mahesh, V. B.: Postpill and pill-related amenorrhea-galactorrhea. Am. J. Obstet. Gynecol. 110, 838–848 (1971)PubMedGoogle Scholar
  40. 40.
    Gershon-Cohen, J., Berger, S. M., Klickstein, H. S.: Roentgenography of breast cancer moderating concept of “biologic predeterminism”. Cancer 16, 961–964 (1963)PubMedGoogle Scholar
  41. 41.
    Goldenberg, V. E., Wiegenstein, L., Mottet, N. K.: Florid breast fibroadenomas in patients taking hormonal oral contraceptives. Am. J. Clin. Pathol. 49, 52–59 (1968)PubMedGoogle Scholar
  42. 42.
    Golditch, I. M.: Postcontraceptive amenorrhea. Obstet. Gynecol. 39, 903–908 (1972)PubMedGoogle Scholar
  43. 43.
    Goldzieher, J. W., Maqueo, M., Ricaud, L., Aguilar, J. A., Canales, E.: Induction of degenerative changes in uterine myomas by high-dosage progestin therapy. Am. J. Obstet. Gynecol. 96, 1078–1087 (1966)PubMedGoogle Scholar
  44. 44.
    Gonzalez-Angulo, A., Salazar, H.: Pathology of the reproductive system, breast and liver in women during hormonal contraception. In: Uterine Contraction: Side Effects of Steroidal Contraceptives. Josimovich, J. B. (Ed.). New York: John Wiley and Sons, Inc., 1973, pp. 343–380Google Scholar
  45. 45.
    Gould, V. E., Wolff, M., Mottet, N. K.: Morphologic features of mammary carcinomas in women taking hormonal contraceptives. Am. J. Clin. Pathol. 57, 139–143 (1972)PubMedGoogle Scholar
  46. 46.
    Graham, J., Graham, R., Hirabayashi, K.: Reversible “cancer” and the contraceptive pill: Report of a case. Obstet. Gynecol. 31, 190–192 (1968)PubMedGoogle Scholar
  47. 47.
    Greenblatt, D. J., Koch-Weser, J.: Oral contraceptives and hypertension: A report from the Boston Collaborative Drug Surveillance Program. Obstet. Gynecol. 44, 412–417 (1974)PubMedGoogle Scholar
  48. 48.
    IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man: Sex Hormones. Lyon: World Health Organization, International Agency for Research on Cancer, 1974, pp. 29–30Google Scholar
  49. 49.
    Inman, W. H. W., Vessey, M. P.: Investigation of deaths from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age. Br. Med. J. 2, 193–199 (1968)PubMedGoogle Scholar
  50. 50.
    Irey, N. S., Norris, H. J.: Intimai vascular lesions associated with female reproductive steroids. Arch. Pathol. 96, 227–234 (1973)PubMedGoogle Scholar
  51. 51.
    Irey, N. S., Manion, W. C., Taylor, H. B.: Vascular lesions in women taking oral contraceptives. Arch. Pathol. 89, 1–8 (1970)PubMedGoogle Scholar
  52. 52.
    Jackson, J. L., Spain, W. T.: Comparative study of combined and sequential antiovulatory therapy on vaginal moniliasis. Am. J. Obstet. Gynecol. 101, 1134–1135 (1968)PubMedGoogle Scholar
  53. 53.
    Jensen, H. K., Hansen, P. A., Blom, J.: Incidence of Candida albicans in women using oral contraceptives. Acta Obstet. Gynecol. Scand. 49, 293–296 (1970)PubMedGoogle Scholar
  54. 54.
    Kaufman, R. H., Reeves, K. O., Dougherty, C. M.: Severe atypical endometrial changes and sequential contraceptive use. JAMA 236, 923–926 (1976)PubMedGoogle Scholar
  55. 55.
    Kelley, H. W., Miles, P. A., Buster, J. E., Scragg, W. H.: Adenocarcinoma of the endometrium in women taking sequential oral contraceptives. Obstet. Gynecol. 47, 200–202 (1976)Google Scholar
  56. 56.
    Kirschstein, R. L., Rabson, A. S., Rusten, G. W.: Infiltrating duct carcinoma of the mammary gland of a Rhesus monkey after administration of an oral contraceptive. A preliminary report. J. Natl. Cancer Inst. 48, 551–556 (1972)PubMedGoogle Scholar
  57. 57.
    Kistner, R. W.: Endometrial alterations associated with estrogen and estrogen-progestin combinations. In: International Academy of Pathology Monograph Number 14, The Uterus. Norris, H. J., Hertig, A. T., Abell, M. R. (Eds.). Baltimore: Williams and Wilkins Co., 1973, pp. 227–254Google Scholar
  58. 58.
    Kline, T. S., Holland, M., Wemple, D.: Atypical cytology with contraceptive hormone medication. Am. J. Clin. Pathol. 53, 215–222 (1970)PubMedGoogle Scholar
  59. 59.
    Koide, S. S., Lyle, K. C.: Unusual signs and symptoms associated with oral contraceptive medication. J. Reprod. Med. 15, 214–224 (1975)PubMedGoogle Scholar
  60. 60.
    Kurman, R. J., Norris, H. J.: Adenosis. (Letter to the Editor.) Obstet. Gynecol. 46, 373–374 (1975)PubMedGoogle Scholar
  61. 61.
    Kusama, S., Spratt, J. S., Donegan, W. L., Watson, F. R., Cunningham, C.: The gross rates of growth of human mammary carcinoma. Cancer 30, 594–599 (1972)PubMedGoogle Scholar
  62. 62.
    Kyriakos, M., Kempson, R. L., Konikov, N. F.: A clinical and pathologic study of endocervical lesions associated with oral contraceptives. Cancer 22, 99–110 (1968)PubMedGoogle Scholar
  63. 63.
    Leis, H. P., Black, M. M., Sall, S.: The pill and the breast. J. Reprod. Med. 16, 5–9 (1976)PubMedGoogle Scholar
  64. 64.
    Liu, W., Koebel, L., Shipp, J., Prisby, H.: Cytologic changes following the use of oral contraceptives. Obstet. Gynecol. 30, 228–232 (1967)PubMedGoogle Scholar
  65. 65.
    Livingston, G. A., Joel, R. V.: The promiscuity pill principle (P-P-P). (Letter to the Editor.) Acta Cytol. 20, 4 (1976)PubMedGoogle Scholar
  66. 66.
    Low, J., Oparil, S.: Oral contraceptive pill hypertension. J. Reprod. Med. 15, 201–208 (1975)PubMedGoogle Scholar
  67. 67.
    Lyon, F. A.: The development of adenocarcinoma of the endometrium in young women receiving long-term sequential oral contraception (report of four cases). Am. J. Obstet. Gynecol. 123, 299–301 (1975)PubMedGoogle Scholar
  68. 68.
    Lyon, F. A., Frisch, M. J.: Endometrial abnormalities occurring in young women on long-term sequential oral contraception. Obstet. Gynecol. 47, 639–643 (1976)PubMedGoogle Scholar
  69. 69.
    Mahgoub, S. El, Karim, M., Ammar, R.: Long term effects of injected progestogens on the morphology of human oviducts. J. Reprod. Med. 8, 288–292 (1972)PubMedGoogle Scholar
  70. 70.
    Maqueo, M., Rice-Wray, E., Calderon, J. J., Goldzieher, J. W.: Ovarian morphology and prolonged use of steroid contraceptives. Contraception 5, 177–185 (1972)PubMedGoogle Scholar
  71. 71.
    Marshall, J. M.: The physiology of the endometrium. In: International Academy of Pathology Monograph Number 14, The Uterus. Norris, H. J., Hertig, A. T., Abell, M. R. (Eds.). Baltimore: Williams and Wilkins Co., 1973, pp. 89–109Google Scholar
  72. 72.
    Masi, A. T., Dugdale, M.: Cerebrovascular diseases associated with the use of oral contraceptives: A review of the English-language literature. Ann. Intern. Med. 72, 111–121 (1970)PubMedGoogle Scholar
  73. 73.
    McQuarrie, G.: Oral contraception. Med. Clin. North Am. 51, 1261–1275 (1967)PubMedGoogle Scholar
  74. 74.
    Melamed, M. R., Flehinger, B. J.: Early incidence rates of precancerous cervical lesions in women using contraceptives. Gynecol. Oncol. 1, 290–298 (1973)Google Scholar
  75. 75.
    Melamed, M. R., Koss, L. G., Flehinger, B. J., Kelisky, R. P., Dubrow, H.: Prevalence rates of uterine cervical carcinoma in situ for women using the diaphragm or contraceptive oral steroids. Br. Med. J. 3, 195–200 (1969)PubMedGoogle Scholar
  76. 76.
    Moghissi, K. S.: Endometrium and endosalpinx of women treated with microdose progestogens. J. Reprod. Med. 14, 217–218 (1975)PubMedGoogle Scholar
  77. 77.
    Moghissi, K. S., Syner, F. M., McBridge, L. C.: Contraceptive mechanism of microdose norethindrone. Obstet. Gynecol. 41, 585–594 (1973)PubMedGoogle Scholar
  78. 78.
    Nelson, L. W., Weikel, J. H., Jr., Reno, F. E.: Mammary nodules in dogs during four years’ treatment with megestrol acetate or chlormadinone acetate. J. Natl. Cancer Inst. 51, 1303–1311 (1973)PubMedGoogle Scholar
  79. 79.
    Ober, W. B.: Synthetic progestagen-oestrogen preparations and endometrial morphology. J. Clin. Pathol. 19, 138–147 (1966)PubMedGoogle Scholar
  80. 80.
    Ober, W. B.: Effects of oral and intrauterine contraceptives on the utrus, ovaries and other organs. Hum. Pathol. 8, 513–517 (1977)PubMedGoogle Scholar
  81. 81.
    Ober, W. B., Decker, A., Clyman, M. J., Roland, M.: Endometrial morphology after sequential medication with mestranol and Chlormadinone. Obstet. Gynecol. 28, 247–253 (1966)PubMedGoogle Scholar
  82. 82.
    Oberti, C., Dabancens, A., Garcia-Huidobro, M., Rodriguez-Bravo, R., Zarnartu, J.: Low dosage oral progestogens to control fertility: II. Morphologic modifications in the gonad and oviduct. Obstet. Gynecol. 43, 285–294 (1974)PubMedGoogle Scholar
  83. 83.
    Ory, H., Naib, Z., Conger, S. B., Hatcher, R. A., Tyler, C. W., Jr.: Contraceptive choice and prevalance of cervical dysplasia and carcinoma in situ. Am. J. Obstet. Gynecol. 124, 573–577 (1976)PubMedGoogle Scholar
  84. 84.
    Osterholzer, H. O., Grillo, D., Kruger, P. S., Dunnihoo, D. R.: The effect of oral contraceptive steroids on branches of the uterine artery. Obstet. Gynecol. 49, 227–232 (1977)PubMedGoogle Scholar
  85. 85.
    Patek, E., Nilsson, L., Johannisson, E., Hellema, M., Bout, J.: Scanning electron microscopic study of the human fallopian tube. Report III. The effect of midpregnancy and of various steroids. Fertil. Steril. 24, 31–43 (1973)PubMedGoogle Scholar
  86. 86.
    Pearlman, A. W.: Breast cancer — influence of growth rate on prognosis and treatment evaluation. A study based on mastectomy scar recurrences. Cancer 38, 1826–1833 (1976)PubMedGoogle Scholar
  87. 87.
    Penman, H. G.: The effect of oral contraceptives on the histology of carcinoma of the breast. J. Pathol. 101, 66–68 (1970)PubMedGoogle Scholar
  88. 88.
    Phillips, N., Duffy, T.: One-hour glucose tolerance in relation to the use of contraceptive drugs. Am. J. Obstet. Gynecol. 116, 91–100 (1973)PubMedGoogle Scholar
  89. 89.
    Piiroinen, O., Rauramo, L.: Oral contraception and uterine size — ultrasonic study. Am. J. Obstet. Gynecol. 122, 349–351 (1975)Google Scholar
  90. 90.
    Plate, W. P.: Ovarian changes after long term oral contraception. Acta Endocrinol. 55, 71–77 (1967)PubMedGoogle Scholar
  91. 91.
    Posner, N. A., Silverstone, F. A., Tobin, E. H., Breuer, J.: Changes in carbohydrate tolerance during longterm oral contraception. Am. J. Obstet. Gynecol. 123, 119–127 (1975)PubMedGoogle Scholar
  92. 92.
    Prakash, S., Scully, R. E.: Sarcoma-like pseudopregnancy changes in uterine leiomyomas: report of a case resulting from prolonged norethindrone therapy. Obstet. Gynecol. 24, 106–109 (1964)PubMedGoogle Scholar
  93. 93.
    Reynolds, S. R. M.: In: Physiology of the Uterus. 2nd ed. New York: Hafner Publishing Company, 1965, Ch. 14, pp. 194–202Google Scholar
  94. 94.
    Rice-Wray, E., Carreu, S., Gorodovsky, J., Esquivel, J., Goldzieher, J. W.: Return of ovulation after discontinuance of oral contraceptives. Fertil. Steril. 18, 212–218 (1967)PubMedGoogle Scholar
  95. 95.
    Robboy, S. J., Welch, W. R.: Microglandular hyperplasia in vaginal adenosis associated with oral contraceptives and prenatal diethylstilbestrol exposure. Obstet. Gynecol. 49, 430–434 (1977)PubMedGoogle Scholar
  96. 96.
    Robson, J. S., Martin, A. M., Ruckley, V. A., MacDonald, M. K.: Irreversible post-partum renal failure: A new syndrome. Q. J. Med. 37, 423–435 (1968)PubMedGoogle Scholar
  97. 97.
    Roland, M., Clyman, M. J., Decker, A., Ober, W. B.: Classification of endometrial response to synthetic progestogen-estrogen compounds. Fertil. Steril. 15, 143–163 (1964)PubMedGoogle Scholar
  98. 98.
    Roland, M., Clyman, M. J., Decker, A., Ober, W. B.: Sequential endometrial alterations during one cycle of treatment with synthetic progestagen-estrogen compounds. Fertil. Steril. 17, 338–350 (1966)PubMedGoogle Scholar
  99. 99.
    Ryan, G. M., Jr., Craig, J., Reid, D. E.: Histology of the uterus and ovaries after long-term cyclic norethynodrel therapy. Am. J. Obstet. Gynecol. 90, 715–725 (1964)PubMedGoogle Scholar
  100. 100.
    Sandmire, H. F., Austin, S. D., Bechtel, R. C.: Carcinoma of the cervix in oral contraceptive steroid and IUD users and nonusers. Am. J. Obstet. Gynecol. 125, 339–345 (1976)PubMedGoogle Scholar
  101. 101.
    Sartwell, P. E., Arthes, F. G., Tonascia, J. A.: Epidemiology of benign breast lesions: Lack of association with oral contraceptive use. New. Engl. J. Med 288, 551–554 (1973)PubMedGoogle Scholar
  102. 102.
    Sartwell, P. E., Masi, A. T., Arthes, F. G., Greene, G. R., Smith, H. E.: Thromboembolism and oral contraceptives: an epidemiologic case-control study. Am. J. Epidemiol. 90, 365–380 (1969)PubMedGoogle Scholar
  103. 103.
    Second report on the oral contraceptives, Advisory Committee on Obstetrics and Gynecology, Food and Drug Administration, Washington, D.C.: U.S. Government Printing Office, 1969Google Scholar
  104. 104.
    Shulman, J. J., Merritt, C. G.: Contraceptive choice and cervical cytology. Am. J. Obstet. Gynecol. 116, 1079–1087 (1973)PubMedGoogle Scholar
  105. 105.
    Silverberg, S. G., Makowski, E. L.: Endometrial carcinoma in young women taking oral contraceptive agents. Obstet. Gynecol. 46, 503–506 (1975)PubMedGoogle Scholar
  106. 106.
    Silverberg, S. G., Makowski, E. L., Roche, W. D.: Endometrial carcinoma in women under 40 years of age. Comparison of cases in oral contraceptive users and non-users. Cancer 39, 592–598 (1977)PubMedGoogle Scholar
  107. 107.
    Smith, R. W.: Hypertension and oral contraception. Am. J. Obstet. Gynecol. 113, 482–487 (1972)PubMedGoogle Scholar
  108. 108.
    Song, J., Mark, M. S., Lawler, M. P., Jr.: Endometrial changes in women receiving oral contraceptives. Am. J. Obstet. Gynecol. 107, 717–728 (1970)PubMedGoogle Scholar
  109. 109.
    Spellacy, W. N.: A review of carbohydrate metabolism and the oral contraceptives. Am. J. Obstet. Gynecol. 104, 448–460 (1969)PubMedGoogle Scholar
  110. 110.
    Spellacy, W. N.: Progestogen and estrogen effects on carbohydrate metabolism. In: Uterine Contraction — Side Effects of Steroidal Contraceptives. Josimovich, J. B. (Ed.). New York: John Wiley & Sons, Inc., 1973, pp. 327–341Google Scholar
  111. 111.
    Spellacy, W. N.: Metabolic effects of oral contraceptives. Clin. Obstet. Gynecol. 17, 53–64 (1974)PubMedGoogle Scholar
  112. 112.
    Spellacy, W. N., Buhi, W. C., Birk, S. A., McCreary, S. A.: Change in glucose and insulin after six months treatment with the oral contraceptive Demulen. Am. J. Obstet. Gynecol. 119, 266–267 (1974)PubMedGoogle Scholar
  113. 113.
    Spellacy, W. N., Zaias, N., Buhi, W. C., Birk, S. A.: Vaginal yeast growth and contraceptive practices. Obstet. Gynecol. 38, 343–349 (1971)PubMedGoogle Scholar
  114. 114.
    Speroff, L., Glass, R. H., Kase, N. G.: Clinical Gynecologic Endocrinology and Infertility. Baltimore: The Williams and Wilkins Company, 1973, pp. 101–102Google Scholar
  115. 115.
    Speroff, L., Glass, R. H., Kase, N. G.: Clinical Gynecologic Endocrinology and Infertility. Baltimore: The Williams and Wilkins Company, 1973, pp. 152–171Google Scholar
  116. 116.
    Steele, S. J., Mason, B., Brett, A.: Amenorrhea after discontinuing combined oestrogen-progestogen oral contraceptives. Br. Med. J. 4, 343–345 (1973)PubMedGoogle Scholar
  117. 117.
    Stern, E., Forsythe, A. B., Youkeles, L., Coffelt, C. F.: Steroid contraceptive use and cervical dysplasia: increased risk of progression. Science 196, 1460–1462 (1977)PubMedGoogle Scholar
  118. 118.
    Taber, B. F.: Breast cancer and oral contraception. J. Reprod. Med. 15, 97–99 (1975)PubMedGoogle Scholar
  119. 119.
    Tapia, H. R., Johnson, C. E., Strong, C. G.: Effect of oral contraceptive therapy on the renin-angiotension system in normotensive and hypertensive women. Obstet. Gynecol. 41, 643–649 (1973)PubMedGoogle Scholar
  120. 120.
    Taylor, H. B.: Oral contraceptives and pathologic changes in the breast. Cancer 28, 1388–1390 (1971)PubMedGoogle Scholar
  121. 121.
    Taylor, H. B., Irey, N. S., Norris, H. J.: Atypical endocervical hyperplasia in women taking oral contraceptives. JAMA 202, 637–639 (1967)PubMedGoogle Scholar
  122. 122.
    Tobon, H.: Malignant hypertension, uremia and hemolytic anemia in a patient on oral contraceptives. Obstet. Gynecol. 40, 681–685 (1972)PubMedGoogle Scholar
  123. 123.
    Tyson, J. E., Andreasson, B., Huth, J., Smith, B., Zacur, H.: Neuroendocrine dysfunction in galactorrhea — amenorrhea after oral contraceptive use. Obstet. Gynecol. 46, 1–11 (1975)PubMedGoogle Scholar
  124. 124.
    Vessey, M. P.: Thromboembolism, cancer and oral contraceptives. Clin. Obstet. Gynecol. 17, 65–78 (1974)PubMedGoogle Scholar
  125. 125.
    Vessey, M. P., Doll, R.: Investigation of relation between use of oral contraceptives and thromboembolic disease. Br. Med. J. 2, 199–205 (1968)PubMedGoogle Scholar
  126. 126.
    Vessey, M. P., Doll, R., Sutton, P. M.: Investigation of the possible relationship between oral contraceptives and benign and malignant breast disease. Cancer 28, 1395–1399 (1971)PubMedGoogle Scholar
  127. 127.
    Vessey, M. P., Doll, R., Sutton, P. M.: Oral contraceptives and breast neoplasia: A retrospective study. Br. Med. J. 3, 719–724 (1972)PubMedGoogle Scholar
  128. 128.
    Wagoner, R. D., Holley, K. E., Johnson, W. J.: Accelerated nephrosclerosis and postpartum acute renal failure in normotensive patients. Ann. Intern. Med. 69, 237–248 (1968)PubMedGoogle Scholar
  129. 129.
    Wiegenstein, L., Tank, R., Gould, V. E.: Multiple breast fibroadenomas in women on hormonal contraceptives. (Letter to the Editor.) New. Engl. J. Med. 284, 676 (1971)PubMedGoogle Scholar
  130. 130.
    Wilkinson, E., Dufour, D. R.: Pathogenesis of microglandular hyperplasia of the cervix uteri. Obstet. Gynecol. 47, 189–195 (1976)PubMedGoogle Scholar
  131. 131.
    Wright, S. W., Fotherby, K., Fairweather, F.: Effect of daily small doses of Norgestrel on ovarian function. J. Obstet. Gynecol. 77, 65–68 (1970)Google Scholar
  132. 132.
    Zacharle, B. J., Richardson, J. A.: Irreversible renal failure secondary to hypertension induced by oral contraceptives. Ann. Intern. Med. 77, 83–85 (1972)Google Scholar
  133. 133.
    Zussman, W. V., Forbes, D. A., Carpenter, R. J.: Ovarian morphology following cyclic norethin-drone — mestranol therapy. Am. J. Obstet. Gynecol. 99, 99–105 (1967)PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1979

Authors and Affiliations

  • George D. Hilliard
  • Henry J. Norris

There are no affiliations available

Personalised recommendations